Puma Biotechnology, Inc. (PBYI) Stock Price & Analysis
Puma Biotechnology, Inc. (PBYI) closed at USD 10.62 on Wednesday, October 28, 2026, down 2.75% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 10.92; the Oct 28, 2026 session ranged USD 10.53–10.95 on volume of 419,532 shares. Market capitalization is $548.21M, with a 52-week range of USD 4.58–11.5 (NMS). Source: Nexqual, retrieved October 29, 2026 at 07:40 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PBYI.md
Key facts (PBYI)
- Last four reported quarters (through Jun 30, 2026): revenue $231M, net income $26.7M (11.6% margin), free cash flow $41.1M (SEC filings).
- Valuation: P/E 20.5x (avg 8.0x at the last 3 fiscal year-ends), EV/EBITDA 12.0x, net cash $86.8M.
- Insider open-market sales, last ~7 months: 10 Form 4 filings, $1.7M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 9 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 3.00 on a 1–5 scale) (1 analysts).
- Total return with dividends: 1Y +105.8% vs S&P 500 +13.6%; 5Y +108.2% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD —, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PBYI)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $253M | $228M | $236M | $230M | $228M | $231M |
| Gross profit | $189M | $173M | $173M | $166M | $170M | — |
| Operating income | $1.3M | $23.7M | $32.6M | $31.0M | $37.3M | $30.4M |
| Net income | -$29.1M | $2K | $21.6M | $30.3M | $31.1M | $26.7M |
| EPS (diluted) | -$0.72 | $0.00 | $0.45 | $0.62 | $0.61 | — |
| Free cash flow | $20.6M | -$15.8M | $26.9M | $38.9M | $41.7M | $41.1M |
| Gross margin | 74.8% | 75.8% | 73.4% | 72.1% | 74.5% | — |
| Operating margin | 0.5% | 10.4% | 13.9% | 13.4% | 16.3% | 13.2% |
| Net margin | -11.5% | 0.0% | 9.2% | 13.1% | 13.6% | 11.6% |
| Revenue growth | +12.5% | -9.9% | +3.3% | -2.2% | -0.9% | — |
| Cash + short-term investments | $69.8M | $46.5M | $48.9M | $86.8M | $91.6M | — |
| Total debt | $102M | $102M | $102M | $68.0M | $22.7M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (PBYI)
P/E 20.5x · P/S 2.4x · EV/EBITDA 12.0x · EV/Sales 2.0x · P/FCF 13.3x · P/B 4.0x · FCF yield 7.50% · Earnings yield 4.87% · Net cash $86.8M · EV $461M
P/E at fiscal year-ends: Dec 2025 9.7x, Dec 2024 4.9x, Dec 2023 9.5x.
Insider sales (SEC Form 4, open-market, last ~7 months) (PBYI)
10 of 10 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Wilson Troy Edward | Director | 5,000 | $46K | 8.3% | Yes | Routine (sold in Jun each year 2023–2025; this trade is outside those months) |
| 2026-09-14 | Cesano Alessandra | Director | 62,150 | $567K | 52.3% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-06 | Auerbach Alan H | President and CEO | 44,058 | $364K | 0.6% | Yes | Routine (sold in Jan & Jul each year 2023–2025) |
| 2026-07-06 | Hunt Douglas M | See Remarks | 8,460 | $70K | 4.1% | Yes | Routine (sold in Jan & Jul each year 2023–2025) |
| 2026-07-06 | Nougues Maximo F | Chief Financial Officer | 9,386 | $78K | 3.9% | Yes | Routine (sold in Jan & Jul each year 2023–2025) |
| 2026-06-12 | Wilson Troy Edward | Director | 10,800 | $78K | 15.2% | Yes | Routine (sold in Jun each year 2023–2025) |
| 2026-06-12 | Stuglik Brian M | Director | 8,100 | $58K | 6.6% | Yes | Routine (sold in Jun each year 2023–2025) |
| 2026-06-12 | Senderowicz Adrian | Director | 27,000 | $194K | 50% | Yes | Routine (sold in Jun each year 2023–2025) |
| 2026-06-12 | Moyes Jay M | Director | 22,000 | $159K | 27.4% | Yes | Routine (sold in Jun each year 2023–2025) |
| 2026-06-12 | Dorval Allison | Director | 11,610 | $84K | 11.3% | Yes | Routine (sold in Jun each year 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (PBYI)
Consensus Hold (mean 3.00 on a 1–5 scale), 1 analysts.
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | TD Cowen | Target raised | Hold | $5 → $6 |
Total return (dividends reinvested) (PBYI)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +105.8% | +108.2% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +106.3% | +15.8% |
| Volatility (annualized) | 61.0% | 70.4% |
| Max drawdown | -25.8% (Feb 2026→Feb 2026) | -68.3% (Feb 2024→Sep 2024) |
PBYI major shareholder filing: Schedule 13D/A, Oct 6, 2026
Alan H. Auerbach filed a Schedule 13D/A with the SEC on Oct 6, 2026, reporting up to 16.00% of the class. A Schedule 13D is filed by an owner of more than 5% who may seek to influence the company. Item 4 (Purpose of Transaction), quoted from the filing:
The information set forth or incorporated in Item 3 above is incorporated herein by reference. From time to time, Mr. Auerbach may acquire beneficial ownership of additional shares of Common Stock or other securities of the Issuer by purchase, as compensation from the Issuer, or otherwise, including, but not limited to, awards of restricted Common Shares, options to purchase Common Shares, and restricted stock units for Common Shares, or dispose of some or all of the shares of Common Stock beneficially owned by Mr. Auerbach in the open market or in privately negotiated transactions (which may be with the Issuer or with third parties) on such terms and at such times as Mr. Auerbach may deem advisable. Mr. Auerbach is the President, Chief Executive Officer and a director of the Issuer. In such capacity, Mr. Auerbach may have influence over the corporate activities of the Issuer and may engage in communications with the Issuer's other directors, members of management and stockholders and third parties regarding the corporate governance, business, operations, strategy or future plans (including proposed corporate transactions of a significant nature) of the Issuer, including any plans or proposals which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Except as described in this Schedule 13D, Mr. …
Source: SEC EDGAR, Schedule 13D/A filed Oct 6, 2026. Quoted word for word; Nexqual adds no interpretation.
PBYI earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.20 | $0.07 | Beat +185.7% | — |
| — | Quarter ended Mar 31, 2026 | −$0.04 | −$0.13 | Beat +69.2% | — |
| — | Quarter ended Dec 31, 2025 | $0.29 | $0.23 | Beat +26.1% | — |
| — | Quarter ended Sep 30, 2025 | $0.21 | $0.09 | Beat +133.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
PBYI recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 6, 2026 | Schedule 13D/A | Alan H. Auerbach: 16.0% of shares, 5%+ holder that may seek to influence the company (amended) “The information set forth or incorporated in Item 3 above is incorporated herein by reference. From time to time, Mr. Auerbach may acquire beneficial ownership of additional shares of Common Stock or other securities of the Issuer by purchase, as compensation from the Issuer, or…” |
| Aug 6, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 6, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
PBYI revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $53.6M | 94.8% | +8.9% |
| Royalty | $2.9M | 5.2% | -9.4% |
| Total revenue | $56.5M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
PBYI suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Knight Therapeutics | “Pursuant to the Knight Agreement, we granted to Knight, under certain of the our intellectual property rights relating to neratinib, an exclusive, sublicensable (under certain circumstances) license (i) to commercialize any product containing neratinib and certain related compounds in Canada (the "Knight Territory"), (ii) to seek and maintain regulatory approvals for the licensed products in the Knight Territory a…” |
| Supplier | Specialised Therapeutics Asia Pte | “Within the STA Territory, STA will be generally responsible for regulatory and commercialization activities, and we will be solely responsible for the manufacturing and supply of the licensed product under a supply agreement entered into between the parties.” |
| Supplier | Medison Pharma | “Pursuant to the Medison Agreement, we granted to Medison, under certain of our intellectual property rights relating to neratinib, an exclusive license to commercialize neratinib and certain related compounds and participate in the named patient supply in Israel (the "Medison Territory"), subject to the terms of the Medison Agreement and the related supply agreement.” |
| Partner | Pfizer (PFE) | “We hold a worldwide exclusive license under our license agreement with Pfizer, as amended (the "Pfizer Agreement") to 21 granted U.S. patents and one pending U.S. patent applications, as well as foreign counterparts thereof, and other patent applications and patents claiming priority therefrom to develop and commercialize certain compounds, including neratinib.” |
| Partner | TAKEDA PHARMACEUTICAL CO LTD (TAK) | “In September 2022, we entered into an exclusive license agreement with Takeda to license the worldwide research and development and commercial rights to alisertib.” |
| Partner | Pfizer and Wyeth | “In July 2021, we entered into a confirmatory agreement with Pfizer and Wyeth LLC ("Wyeth"), confirming that the rights granted to us by Pfizer under the Pfizer Agreement included Wyeth's rights in neratinib (oral), neratinib (intravenous), PB357, and certain related compounds.” |
| Partner | CANbridge Biomed | “On February 24, 2021, we resolved a dispute with our former partner CANbridge Biomed Limited and terminated our sub-license agreement.” |
| Partner | Bixink Therapeutics | “During the second quarter of 2020, we entered into a sub-license agreement (the "Bixink Agreement") with Bixink Therapeutics Co., Ltd. ("Bixink").” |
| Competitor | Eli Lilly (LLY) | “Our competitors include, but are not limited to, Genentech, Novartis, Roche, Boehringer Ingelheim, Lilly, Merck, AbbVie, Pfizer, Amgen, Daiichi Sankyo, Jazz and Seagen.” |
| Competitor | Merck (MRK) | “Our competitors include, but are not limited to, Genentech, Novartis, Roche, Boehringer Ingelheim, Lilly, Merck, AbbVie, Pfizer, Amgen, Daiichi Sankyo, Jazz and Seagen.” |
| Competitor | AbbVie (ABBV) | “Our competitors include, but are not limited to, Genentech, Novartis, Roche, Boehringer Ingelheim, Lilly, Merck, AbbVie, Pfizer, Amgen, Daiichi Sankyo, Jazz and Seagen.” |
Quoted from the company's 10-K filed Feb 26, 2026.
PBYI customer concentration
In the period ended Dec 31, 2025, 5 direct customers each accounted for at least 10% (27.3%, 17%, 16.4%, 13.1%, 10.6%) of revenue, per the company's 10-K filed Feb 26, 2026. The company does not name them.
PBYI analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter (ends Dec 2026) | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2026) | — | — | — | $0 | — |
| Next fiscal year (ends Dec 2027) | — | — | — | $0 | — |
Key Statistics (as of October 29, 2026 at 07:40 UTC)
| Price | USD 10.62 |
|---|---|
| Change | ▼ 2.75% (down) |
| Previous Close | USD 10.92 |
| Open | USD 10.83 |
| Day Range | USD 10.53 – 10.95 |
| 52-Week Range | USD 4.58 – 11.5 |
| Volume | 419,532 shares |
| Market Cap | $548.21M |
| Exchange | NMS |
Technical Analysis (PBYI)
Nexqual's technical model rates PBYI "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 29, 2026 at 07:40 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 57.24 (neutral) |
| vs SMA50 | Above (USD 9.77) |
| MACD | 0.36 (positive) |
Analyst Ratings (PBYI)
Wall Street analysts rate PBYI "Hold" based on 1 analysts, per Nexqual as of October 29, 2026 at 07:40 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 1 |
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (PBYI)
| Next Earnings Date | 2026-11-05 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.2 vs est 0.07 ▲ beat |
| 2026-03-31 | USD -0.04 vs est -0.13 ▲ beat |
| 2025-12-31 | USD 0.29 vs est 0.23 ▲ beat |
| 2025-09-30 | USD 0.21 vs est 0.09 ▲ beat |
Source: Nexqual, October 29, 2026 at 07:40 UTC.
Financials & Fundamentals (PBYI)
| Total Revenue | $231.24M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +7.80% |
| Gross Margin | +74.83% |
| Operating Margin | +13.42% |
| Profit Margin | +11.55% |
| ROE | +21.97% |
| Debt / Equity | 0.03 |
| Current Ratio | 2.91 |
| Total Cash | $93.90M |
| Total Debt | $4.82M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $41.14M (17.8% of revenue) |
Source: Nexqual, October 29, 2026 at 07:40 UTC.
Financial Health Score (PBYI)
Nexqual rates Puma Biotechnology, Inc.'s overall financial health "Solid" across five dimensions, as of October 29, 2026 at 07:40 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 75%, operating 13% (last 4 quarters to Jun 2026, SEC) |
| Balance Sheet | Strong — $87M cash and investments, no debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $41M (last 4 quarters to Jun 2026, SEC), 18% margin |
| Efficiency | Solid — ROE 19%, ROA 13.9% (last 4 quarters, SEC) |
Ownership (PBYI)
| Insider Ownership | +15.37% |
|---|---|
| Institutional Ownership | +75.85% |
| Shares Outstanding | 51.62M |
| Float | 40.34M |
| Short % of Float | +10.30% |
Source: Nexqual, October 29, 2026 at 07:40 UTC.
Leadership (PBYI)
Puma Biotechnology, Inc. is led by Alan H. Auerbach, Founder, Chairman, President, CEO & Secretary, per Nexqual as of October 29, 2026 at 07:40 UTC.
| Founder, Chairman, President, CEO & Secretary | Alan H. Auerbach |
|---|---|
| CFO & Principal Accounting Officer | Maximo F. Nougues |
| Senior Director of Investor Relations | Mariann Ohanesian |
| Senior Vice President of Marketing | Heather Blaber |
| Senior Vice President of Sales | Roger L. Storms |
Major Backers & Investors (PBYI)
Notable institutional backers of Puma Biotechnology, Inc. include Acorn Capital Advisors, LLC , American Century Companies Inc, Acadian Asset Management. LLC, according to Nexqual as of October 29, 2026 at 07:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Acorn Capital Advisors, LLC | 8% |
| American Century Companies Inc | 4.49% |
| Acadian Asset Management. LLC | 3.98% |
| Renaissance Technologies | 3.56% |
| LSV Asset Management | 3.13% |
| Fidelity | 0.94% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.37% |
| Vanguard Group | 7.1% |
| Dimensional Fund Advisors | 2.94% |
| Geode Capital | 2.59% |
Source: Nexqual, October 29, 2026 at 07:40 UTC.
From Puma Biotechnology, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- As of December 31, 2025, NERLYNX has received approval for the treatment of certain patients with extended adjuvant and/or metastatic HER2-positive breast cancer in more than 40 countries outside the United States, including the European Union ("EU"), China, Latin America, Australia, Canada, and Hong Kong.
- In February 2020, the FDA approved our supplemental New Drug Application ("NDA") for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
Partnerships
- In September 2022, we entered into an exclusive license agreement with Takeda to license the worldwide research and development and commercial rights to alisertib.
- In February 2013, we reached agreement with the FDA under a Special Protocol Assessment ("SPA") for our Phase III clinical trial (PUMA-NER-1301 or the NALA trial) of neratinib in patients with HER2-positive metastatic breast cancer who have failed two or more prior treatments (third-line disease).
Legal & Regulatory Risks (Item 1A, quoted)
- The results of our clinical trials may not support our drug candidate claims.
- Regulatory approval for any approved product is limited by the FDA and foreign regulatory authorities to those specific indications and conditions for which clinical safety and efficacy have been demonstrated as set forth on the product label. If we market our products for uses beyond such approved indications, we could be subject to enforcement action, which could have a material adverse effect on our business.
- We are subject to federal, state and foreign healthcare fraud and abuse laws, false claims laws and physician payment transparency laws. Failure to comply with these laws may subject us to substantial penalties.
- We are dependent on international third-party sub-licensees for the development and commercialization of NERLYNX in several countries outside the United States. The failure of these sub-licensees to meet their contractual, regulatory or other obligations could adversely affect our business.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:40 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt